Efficacy and safety of new adjuvants.
Aucouturier
J
J
Vaccine Department, SEPPIG, 75 Quai d'Orsay, 75321 Paris, France.
Ganne
V
V
Laval
A
A
D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D001426:Bacterial Proteins; D001427:Bacterial Toxins / Q000276:immunology; D001428:Bacterial Vaccines / Q000494:pharmacology*; D001884:Bordetella / Q000276:immunology; D005334:Fever / Q000139:chemically induced; D007249:Inflammation; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010326:Pasteurella Infections / Q000276:immunology*; D016979:Pasteurella multocida / Q000276:immunology*; D012449:Safety; D013552:Swine; D011503:Transglutaminases; D014613:Vaccines, Attenuated / Q000494:pharmacology; D010566:Virulence Factors, Bordetella
D000276:Adjuvants, Immunologic; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D001428:Bacterial Vaccines; C062258:Pasteurella multocida toxin; D014613:Vaccines, Attenuated; D010566:Virulence Factors, Bordetella; C060969:dermonecrotic toxin, Bordetella; D011503:Transglutaminases